secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001818331-25-000105
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M
--------------------------------------------------------------------

- Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).
- Adjusted net income $15.0M vs. loss of $2.0M a year ago; GAAP net income $10.8M.
- Adjusted gross margin expanded to 71% from 62% in Q2 2024.
- Acquired Fabric Genomics for $33.2M in cash, net of cash acquired.
- AAP now recommends exome/genome as first-line test for children with global developmental delay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000105/0001818331-25-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000105/wgs-20250729.htm
  HTML page:      https://secwatch.observer/filing/0001818331-25-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer